Nephrogenic Systemic Fibrosis

On this page

NSF Introduction - Gadolinium's Dark Fibrosis

  • Rare, debilitating, and potentially fatal systemic fibrosing disorder.
  • Strongly associated with exposure to Gadolinium-Based Contrast Agents (GBCAs).
  • Primarily identified in patients with pre-existing significant renal dysfunction:
    • Acute Kidney Injury (AKI).
    • Chronic Kidney Disease (CKD) Stage 4 or 5 ($eGFR < \textbf{30} \text{ mL/min/1.73}\text{m}^2$).
    • Patients requiring dialysis (hemodialysis or peritoneal).
  • Characterized by progressive fibrosis of skin, joints, muscles, and internal organs. Nephrogenic Systemic Fibrosis: Cutaneous & Systemic

⭐ Most NSF cases are linked to older, group I (linear, higher risk) GBCAs, especially gadodiamide.

Pathogenesis & Risk Factors - Unmasking the Triggers

  • Mechanism: Dissociation of Gadolinium (Gd³⁺) from less stable GBCAs (transmetallation) → free Gd³⁺ tissue deposition → recruits circulating fibrocytes (CD34+) → ↑collagen, fibrosis. TGF-β1 implicated.
  • Key Risk Factors:
    • Renal Impairment (Highest Risk):
      • Severe CKD (eGFR < 30 mL/min/1.73m²), AKI.
      • Dialysis patients (HD/PD).
    • GBCA Type & Dose:
      • ↑ Risk: Group I (linear, less stable) GBCAs (e.g., Gadodiamide).
      • ↓ Risk: Group II (macrocyclic, more stable) GBCAs.
      • High or repeated doses.
    • Concurrent Pro-inflammatory States: Sepsis, major surgery, active infection, thrombosis.
    • Metabolic acidosis. Pathophysiology of Nephrogenic Systemic Fibrosis

⭐ Group I GBCAs (linear) in patients with eGFR < 30 mL/min/1.73m² pose the greatest NSF risk.

Clinical Features & Diagnosis - Spotting the Signs

  • Onset: 2-4 weeks (can be days to years) post-GBCA.
  • Skin (Key):
    • Symmetrical, painful, itchy, red plaques/papules → hard, "woody" skin.
    • "Peau d'orange" look.
    • Sites: Extremities (spares face), trunk.
    • Joint contractures, ↓ mobility. Nephrogenic Systemic Fibrosis skin changes
  • Systemic: Fibrosis of lungs, heart, muscles; can be fatal.
  • Diagnosis:
    • History: GBCA + eGFR < 30 mL/min/1.73m².
    • Clinical skin changes.
    • Deep skin biopsy: Spindle cells, ↑collagen, mucin, CD34+ fibrocytes, minimal inflammation.

⭐ Strongly linked to Group I GBCAs in severe renal dysfunction (eGFR < 30 mL/min/1.73m²) or AKI.

Prevention & Management - Shielding & Strategies

  • Prevention First: 📌 S.A.F.E.R. approach for GBCAs:
    • Screen: Identify high-risk (eGFR < 30 mL/min/1.73m², AKI).
    • Avoid: Group I GBCAs (e.g., gadodiamide).
    • Favour: Group II/III agents (e.g., gadobutrol) if contrast essential.
    • Ensure: Lowest effective dose, adequate pre/post-hydration.
    • Renal Dialysis Patients: Consider prompt HD (ideally within 2-4 hrs) post-GBCA.
  • Management Strategies:
    • No definitive cure; supportive & symptomatic focus.
    • Physiotherapy: For contractures, skin changes.
    • Pain management.
    • Experimental: Extracorporeal Photopheresis (ECP), sodium thiosulfate.
    • Renal transplant: May halt/improve.

⭐ The cornerstone of NSF prevention is strict avoidance of Group I GBCAs in patients with eGFR < 30 mL/min/1.73m².

High‑Yield Points - ⚡ Biggest Takeaways

  • Nephrogenic Systemic Fibrosis (NSF) is strongly linked to gadolinium-based contrast agents (GBCAs), especially older, less stable Group I GBCAs.
  • Primarily affects patients with severe renal dysfunction (eGFR < 30 mL/min/1.73m²), particularly those on dialysis.
  • Characterized by progressive, painful skin thickening and hardening, often on extremities, leading to joint contractures.
  • Can involve systemic fibrosis affecting internal organs like lungs, heart, and muscles.
  • No definitive cure exists; management focuses on improving renal function (e.g., kidney transplant) and physiotherapy.
  • Prevention is crucial: screen for renal impairment; avoid GBCAs in high-risk patients or use safer Group II/III GBCAs cautiously.
  • Deep skin biopsy showing spindle cells, thickened collagen bundles, and elastic fibers confirms diagnosis.

Practice Questions: Nephrogenic Systemic Fibrosis

Test your understanding with these related questions

Gadolinium is a contrast agent used for:

1 of 5

Flashcards: Nephrogenic Systemic Fibrosis

1/7

_____ has osmolarity of 300 mOsm (Iso-osmolar).

TAP TO REVEAL ANSWER

_____ has osmolarity of 300 mOsm (Iso-osmolar).

Non-ionic Dimer

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial